Optimize Meds for Comorbidities in Nonalcoholic Fatty Liver Disease

September 2017

You'll see more patients with nonalcoholic fatty liver disease (NAFLD).

Up to 100 million Americans have this buildup of fat in the liver...usually without any symptoms. It often goes hand in hand with obesity, dyslipidemia, insulin resistance, and diabetes.

About 20% of patients with NAFLD have nonalcoholic steatohepatitis (NASH)...the more severe form with inflammation and sometimes fibrosis. It's set to be the top reason for liver transplants in the U.S. by 2020.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Hypertension Watch for Commonly Used Meds and Supplements That May Increase Blood Pressure
Liver Disease Optimize Meds for Comorbidities in Nonalcoholic Fatty Liver Disease
Neurology & Pain Consider Pros and Cons of Meds for Diabetic Peripheral Neuropathy
Women's Health Help Pregnant Women Choose a Prenatal Vitamin
Cannabinoids Explain Risks and Benefits of Medical Marijuana
Dermatology Tell Patients to Think of New Tattoos as Wounds
Multiple Sclerosis Help Patients Manage Side Effects of Multiple Sclerosis Meds
Menopause New Intrarosa Is an Alternative to Vaginal Estrogen for Dyspareunia
Anticoagulants Use a Low-Molecular-Weight Heparin for Most Patients With Cancer-Associated VTE
Insulin Know How Tresiba Compares to Other Basal Insulins for Type 2 Diabetes
Med Safety Be Aware of Standardized Concentrations for Compounded Oral Liquid Medications

Optimize Meds for Comorbidities in Nonalcoholic Fatty Liver Disease

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents